Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial.
Sixty-four patients with non-insulin-dependent diabetes mellitus were treated with a combination of insulin and oral sulfonylurea therapy in a double-blind, placebo-controlled trial during a 12-month period. Combination therapy lowered fasting glucose levels significantly only at the third and fourth months of treatment. Glycohemoglobin levels were significantly lower than control at 3 and 6 months whereas C-peptide levels were significantly increased at 3 and 9 months. Responders exhibited as much as a 50% reduction in total insulin dose compared with nonresponders or control subjects. These results suggest that combination therapy affords transient metabolic improvement in certain patients with non-insulin-dependent diabetes. Improvement in fasting glucose levels appears to be mediated by enhanced insulin secretion. Combination therapy may increase the cost of treatment by nearly 50% and appears warranted only in selected patients.
D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D005905:Glyburide; D006442:Glycated Hemoglobin; D007328:Insulin